Related Experiment Video

Updated: Apr 23, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Should we replace dexamethasone, cytarabine, and cisplatin for relapsed lymphoma?

Christian Gisselbrecht1

  • 1Hôpital Saint Louis Paris, Paris, France christian.gisselbrecht@sls.aphp.fr.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|October 1, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

809

Related Experiment Videos

Last Updated: Apr 23, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

809

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K

Articles linked to this work by shared authors, journal, and citation graph.

Large B-cell lymphoma: The LYSA pragmatic guidelines.

European journal of cancer (Oxford, England : 1990)·2025

Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?

British journal of haematology·2022

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

The Lancet. Haematology·2022

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.

HemaSphere·2021

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.

Blood advances·2021

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia.

HemaSphere·2021

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us